AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11039684 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐focused cognitive‐behaviour therapy (CBT)
Number of subjects: 50
Study 11039684 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus parent involvement
Number of subjects: 50
Study 11039684 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 50
Study 11039684 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 50
Study 8900982 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic drum rotation for 12 minutes
Number of subjects: 49
Study 1825144 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 0
Study 1825144 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 0
Study 1825144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain response after 4 weeks
Number of subjects: 0
Study 6661342 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administration during exercise
Number of subjects: 9
Study 6661342 — intervention group
Group type: COMPARATOR
Intervention: Placebo periods
Number of subjects: 9
Study 30951598 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Blood Flow Restriction Training (BFRT)
Number of subjects: 60
Study 30951598 — intervention group
Group type: COMPARATOR
Intervention: Placebo Blood Flow Restriction Training (standard of care)
Number of subjects: 60
Study 28990807 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy for tinnitus
Number of subjects: 146
Study 28990807 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study 26238576 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 659
Study 26238576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study 24569045 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/d
Number of subjects: 139
Study 24569045 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 10-20 mg/d
Number of subjects: 139
Study 24569045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 23257370 — intervention group
Group type: EXPERIMENTAL
Intervention: pPCI with thrombectomy (Group T)
Number of subjects: 208
Study 20061838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy
Number of subjects: 0
Study 20061838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin in combination therapy with two antihistamines
Number of subjects: 0
Study 20061838 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine alone
Number of subjects: 0
Study 20061838 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine in combination with two antihistamines
Number of subjects: 0
Study 16984938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (60 mg daily for the first week and 40 mg daily for the second week)
Number of subjects: 21
Study 16984938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15886179 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizations implementing more HIPAA Privacy Rule requirements
Number of subjects: 0
Study 15886179 — intervention group
Group type: COMPARATOR
Intervention: Organizations not implementing HIPAA Privacy Rule requirements
Number of subjects: 0
Study 12944994 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 0
Study 12944994 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cytotoxic therapy
Number of subjects: 0
Study 10567755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripedal stance on three remaining holds for vertical forces
Number of subjects: 1
Study 10567755 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedal stance on two laterally opposite holds (left foot and left holds) for horizontal forces
Number of subjects: 1
Study 8949825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of edrophonium 1 mg kg‐1 and exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma
Number of subjects: 40
Study 8949825 — intervention group
Group type: COMPARATOR
Intervention: Control group (spontaneous recovery)
Number of subjects: 40
Study 8949825 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 (group ED)
Number of subjects: 40
Study 8949825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma (group PCHE)
Number of subjects: 40
Study 8949825 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 and exogenous PCHE (combination group)
Number of subjects: 40
Study 8949825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous PCHE (group PCHE)
Number of subjects: 40
Study 2024224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate
Number of subjects: 99
Study 2024224 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and clindamycin
Number of subjects: 99
Study 7014073 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg doxpicomine
Number of subjects: 43
Study 7014073 — intervention group
Group type: COMPARATOR
Intervention: 8 mg morphine
Number of subjects: 43
Study 7014073 — intervention group
Group type: COMPARATOR
Intervention: 4 mg morphine
Number of subjects: 43
Study 31833868 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis during the third trimester
Number of subjects: 145
Study 31833868 — intervention group
Group type: EXPERIMENTAL
Intervention: No antepartum heparin prophylaxis
Number of subjects: 145
Study 31833868 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous thromboembolism
Number of subjects: 145
Study 31833868 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of outcomes
Number of subjects: 145
Study 31301146 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive PAD (red LED, 635 nm, photosensitive dye, 0.01% tolonium chloride)
Number of subjects: 20
Study 31301146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjunctive PAD)
Number of subjects: 20
Study 31301146 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive PAD
Number of subjects: 20
Study 28160084 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐3 PUFA (2330 mg day‐1)
Number of subjects: 30
Study 28160084 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 30
Study 28160084 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 30
Study 27969041 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily journal writing as reinforcement for resourcefulness training (RT) over a four-week period.
Number of subjects: 0
Study 24438517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (text-message and voucher component)
Number of subjects: 2550
Study 24438517 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 2550
Study 24438517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 2550
Study 22406990 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS + high-dose oral sirolimus (initial dose of 15 mg, followed by 6 mg/day for four weeks)
Number of subjects: 45
Study 22406990 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS + low-dose sirolimus (6 mg followed by 2 mg daily for four weeks)
Number of subjects: 45
Study 22406990 — intervention group
Group type: COMPARATOR
Intervention: BMS without sirolimus
Number of subjects: 45
Study 22406990 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (BMS + high-dose sirolimus, BMS + low-dose sirolimus, BMS without sirolimus)
Number of subjects: 45
Study 19054608 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNTA) treatment
Number of subjects: 21
Study 19054608 — intervention group
Group type: COMPARATOR
Intervention: Control group (no overactive bladder symptoms)
Number of subjects: 21
Study 17876365 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS at T5‐T6 region
Number of subjects: 8
Study 17876365 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS at T1‐T2 region
Number of subjects: 8
Study 17876365 — intervention group
Group type: COMPARATOR
Intervention: Control (SCS off) during CPT
Number of subjects: 8
Study 17876365 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS at T5‐T6 region during CPT
Number of subjects: 8
Study 15236635 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.25%
Number of subjects: 50
Study 15236635 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.32%
Number of subjects: 50
Study 15236635 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.40%
Number of subjects: 50
Study 15236635 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.50%
Number of subjects: 50
Study 15236635 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25%
Number of subjects: 50
Study 12688173 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (non-CPB)
Number of subjects: 144
Study 9829604 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL, energy provision 1 x the initial predicted basal metabolic rate; 3 days)
Number of subjects: 6
Study 9829604 — intervention group
Group type: COMPARATOR
Intervention: Continuous nasogastric infusion of colored water (2 days)
Number of subjects: 6
Study 9829604 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL)
Number of subjects: 6
Study 7917576 — intervention group
Group type: EXPERIMENTAL
Intervention: QCT (Quantitative Computed Tomography)
Number of subjects: 45
Study 7917576 — intervention group
Group type: COMPARATOR
Intervention: DPA (Dual Energy Photon Absorptiometry)
Number of subjects: 45
Study 2780070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg for upper limb pain, 20 mg for lower limb pain)
Number of subjects: 16
Study 2780070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2780070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 16
Study 1108735 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyinosinic‐polycytidylic acid (In‐Cn)
Number of subjects: 0
Study 1108735 — intervention group
Group type: COMPARATOR
Intervention: IDU (Idoxuridine)
Number of subjects: 0
Study 1108735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with In‐Cn
Number of subjects: 0
Study 1108735 — intervention group
Group type: COMPARATOR
Intervention: IDU or In‐Cn
Number of subjects: 0
Study 31399446 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuanbi antong granules (XAG)
Number of subjects: 300
Study 31399446 — intervention group
Group type: COMPARATOR
Intervention: XAG placebo
Number of subjects: 300
Study 31399446 — intervention group
Group type: EXPERIMENTAL
Intervention: XAG
Number of subjects: 300
Study 29322923 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear polynomial (degree 1 polynomial) using correlation analysis
Number of subjects: 0
Study 29322923 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear polynomial (degree 1 polynomial) using apoptosis pathway gene selection
Number of subjects: 0
Study 25732032 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatment (use of aspirin and analgesics only, no reperfusion)
Number of subjects: 45091
Study 25732032 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (any treatment including antithrombotics or anticoagulants, but no reperfusion)
Number of subjects: 45091
Study 25732032 — intervention group
Group type: COMPARATOR
Intervention: Reperfusion treatment (thrombolysis and/or percutaneous coronary intervention)
Number of subjects: 45091
Study 25732032 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatment
Number of subjects: 45091
Study 23788306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) bolus of GP IIb/IIIa inhibitor
Number of subjects: 77
Study 23788306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of GP IIb/IIIa inhibitor
Number of subjects: 77
Study 21464382 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation of multiple passive measures (eg, stair gates, cabinet locks, and smoke detectors)
Number of subjects: 355
Study 21464382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 355
Study 19187417 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational and physical therapy sessions to instruct participants in compensatory strategies, home modifications, home safety, fall recovery techniques, and balance and muscle strength exercises.
Number of subjects: 319
Study 19187417 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 319
Study 16457132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone (300-900 mg daily)
Number of subjects: 120
Study 16457132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16457132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone
Number of subjects: 120
Study 15544685 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid booklet for menorrhagia
Number of subjects: 363
Study 15544685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 363
Study 15544685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trial group (not specified as intervention or control)
Number of subjects: 363
Study 11408847 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6-g load then 2 g/hr)
Number of subjects: 22
Study 11408847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactated Ringer's solution)
Number of subjects: 22
Study 9312708 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 mm Polypin
Number of subjects: 183
Study 9312708 — intervention group
Group type: COMPARATOR
Intervention: Metal implants
Number of subjects: 183
Study 9312708 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyactide implants
Number of subjects: 183
Study 9312708 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientruded polyactide screws
Number of subjects: 183
Study 8358527 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser ablation
Number of subjects: 51
Study 8358527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon‐alpha
Number of subjects: 51
Study 8358527 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser ablation plus intramuscular interferon‐alpha
Number of subjects: 51
Study 8358527 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 3117084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) administered to the nasal mucosa 30 min before provocation with histamine
Number of subjects: 0
Study 3117084 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine administered to the nasal mucosa 30 min before provocation with histamine
Number of subjects: 0
Study 3117084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen administered to the nasal mucosa 30 min before provocation with histamine
Number of subjects: 0
Study 3117084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline control solution) administered prior to provocation
Number of subjects: 0
Study 3117084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG), clemastine, and ketotifen administered to the nasal mucosa 30 min before provocation with allergen
Number of subjects: 0
Study 30968235 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention for 3 weeks
Number of subjects: 56
Study 30968235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 56
Study 28318767 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB and MenC-CRM
Number of subjects: 251
Study 28318767 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM alone
Number of subjects: 251
Study 25433046 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-head two-thumb encircling technique (OTTT)
Number of subjects: 50
Study 25433046 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique (TFT)
Number of subjects: 50
Study 23394492 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmacytoid carcinoma (PUC)
Number of subjects: 205
Study 23394492 — intervention group
Group type: COMPARATOR
Intervention: Urothelial carcinoma (UC)
Number of subjects: 205
Study 23394492 — intervention group
Group type: COMPARATOR
Intervention: Micropapillary carcinoma (MPC)
Number of subjects: 205
Study 21057336 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term inpatient psychotherapeutic support (n=59)
Number of subjects: 113
Study 21057336 — intervention group
Group type: COMPARATOR
Intervention: Long-term outpatient psychotherapeutic support (n=54)
Number of subjects: 113
Study 17925050 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release vitamin C tablets (500 mg/d) and vitamin E (182 mg/d) for 4 weeks
Number of subjects: 0
Study 17925050 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 0
Study 17925050 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-nourished subjects consuming 600 g fruits and vegetables or equivalent vitamins and minerals for 24 days
Number of subjects: 0
Study 16194620 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance training program twice a week for five months
Number of subjects: 43
Study 16194620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 43
Study 15271002 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreground object presented in a semantically consistent setting
Number of subjects: 0
Study 15271002 — intervention group
Group type: EXPERIMENTAL
Intervention: Background presented with a semantically consistent foreground object
Number of subjects: 0
Study 15271002 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects presented in isolation (without backgrounds)
Number of subjects: 0
Study 15271002 — intervention group
Group type: EXPERIMENTAL
Intervention: Backgrounds presented without foreground objects
Number of subjects: 0
Study 15271002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both objects and backgrounds reported together
Number of subjects: 0
Study 10786405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole monodose vaginal suppository only (group O)
Number of subjects: 77
Study 10786405 — intervention group
Group type: COMPARATOR
Intervention: Sertaconazole monodose vaginal suppository combined with sertaconazole cream applied to the vulvar area for 7 days (group OC)
Number of subjects: 77
Study 9324175 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg intravenously
Number of subjects: 165
Study 9324175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 8267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 25 mg
Number of subjects: 12
Study 8267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 50 mg
Number of subjects: 12
Study 8267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 75 mg
Number of subjects: 12
Study 3009726 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative CAP chemotherapy (Cytoxan, Adriamycin, and cisplatin)
Number of subjects: 141
Study 3009726 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette‐Guerin (BCG) and levamisole immunotherapy
Number of subjects: 141
Study 28751531 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer-specific ankle braces worn on both ankles during soccer training and matches
Number of subjects: 0
Study 28751531 — intervention group
Group type: COMPARATOR
Intervention: Usual soccer play without ankle braces
Number of subjects: 0
Study 28810359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (text reminders and supportive counseling)
Number of subjects: 115
Study 28810359 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 115
Study 28810359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherers (external regulation)
Number of subjects: 115
Study 28810359 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 115
Study 26482473 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychological training of community midwives (CMWs) providing psychological support sessions to pregnant women.
Number of subjects: 298
Study 26482473 — intervention group
Group type: EXPERIMENTAL
Intervention: Community midwives providing psychological support sessions.
Number of subjects: 298
Study 24604243 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 100 mg
Number of subjects: 0
Study 24604243 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 400 mg once daily for 14 days
Number of subjects: 0
Study 24604243 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 300 mg once daily for 11 days
Number of subjects: 0
Study 24604243 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant with ketoconazole
Number of subjects: 0
Study 24604243 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant with diltiazem
Number of subjects: 0
Study 22313564 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dexamethasone
Number of subjects: 70
Study 22313564 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo solution
Number of subjects: 70
Study 20189654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 1025
Study 20189654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 1025
Study 20189654 — intervention group
Group type: COMPARATOR
Intervention: Sham injections (control for MARINA)
Number of subjects: 1025
Study 20189654 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT, control for ANCHOR)
Number of subjects: 1025
Study 18054727 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 21
Study 18054727 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SAC)
Number of subjects: 21
Study 15635348 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of S oblonga extract
Number of subjects: 39
Study 15635348 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of S oblonga extract (control)
Number of subjects: 39
Study 12131561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg o.i.d.
Number of subjects: 18